Skip to main content

Table 2 Clinical and demographic characteristics of eligible cases

From: A multicenter study of artificial intelligence-aided software for detecting visible clinically significant prostate cancer on mpMRI

 

Hospital_1

(N = 332)

Hospital_2

(N = 63)

Hospital_3

(N = 85)

Overall

(N = 480)

Reference standards, n (%)

Negative

263 (79.2)

15 (23.8)

22 (25.9)

300 (62.5)

Positive

69 (20.8)

48 (76.2)

63 (74.1)

180 (37.5)

Age (years)

65.5 ± 11.0

70.4 ± 8.1

69.3 ± 7.4

66.8 ± 10.2

tPSA (ng/ml)

6.5 [0.16, 43.0]

14.4 [4.8, 100]

15.1 [1.5, 100]

7.69 [0.2, 100]

fPSA (ng/ml)

1.0 [0.2, 11.6]

1.8 [0.4, 23.2]

1.6 [0.3, 50.0]

1.2 [0.1, 50.0]

ISUP Grade Group, n (%)

1

0 (0.0)

6 (9.5)

15 (17.6)

21 (4.4)

2

34 (10.2)

13 (20.6)

10 (11.8)

57 (11.9)

3

10 (3.0)

13 (20.6)

9 (10.6)

32 (6.7)

4

5 (1.5)

9 (14.3)

14 (16.5)

28 (5.8)

5

2 (0.6)

8 (12.7)

16 (18.8)

26 (5.4)

Positive but missing

18 (5.4)

0 (0.0)

2 (2.4)

20 (4.2)

No Cancer

263 (79.2)

14 (22.2)

19 (22.4)

296 (61.7)

PI-RADS, n (%)

2

202 (60.8)

20 (31.7)

15 (17.6)

237 (49.4)

3

76 (22.9)

18 (28.6)

26 (30.6)

120 (25.0)

4

21 (6.3)

3 (4.8)

3 (3.5)

27 (5.6)

5

33 (10.0)

22 (34.9)

41 (48.3)

96 (20.0)

Zone distribution of lesions in patients with PCa, n (%)

PZ

14 (20.3)

12 (25.0)

13 (20.6)

39 (21.7)

TZ

11 (15.9)

9 (18.8)

8 (12.7)

28 (15.6)

PZ and TZ

44 (63.8)

27 (56.3)

42 (66.7)

113 (62.8)

Median volume of lesions in patients with PCa, n (%)

1.1 [0.8, 2.2]

2.3 [1.1, 4.7]

3.2 [1.9, 7.1]

2.0 [1.0, 4.8]

  1. PSA = prostate-specific antigen, SD = standard deviation, ISUP = International Society of Urological Pathology, PI-RADS = Prostate Imaging Reporting and Data System, PZ = peripheral zone, TZ = transition zone
  2. Quantitative variables were given as the mean ± SD for normalized data and as the median [minimum, maximum] for nonnormalized data. The categorical variables are given as absolute frequency (relative frequency)